Journal
ORGANIC PROCESS RESEARCH & DEVELOPMENT
Volume 15, Issue 1, Pages 104-111Publisher
AMER CHEMICAL SOC
DOI: 10.1021/op100204u
Keywords
-
Categories
Ask authors/readers for more resources
AMG 837 (1) is a novel GPR40 agonist selected for clinical development for the treatment of type 2 diabetes. A lysine salt was initially identified as a development form. However, due to the poor crystallinity and severe hygroscopicity of this form, investigations on the free acid form of the drug substance and salt screening were conducted to identify an acceptable physical form for long-term development. A sodium and calcium salt were identified as potentially viable phases, and polymorph screening was conducted on both. The quality attributes of the salts were then compared to determine which phase would be preferred for development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available